2022-01-01
2022-12-31
0000078003
pfe:OncologyMember
pfe:ElrexfioMember
pfe:BiopharmaSegmentMember
2024-01-01
2024-12-31
0000078003
pfe:OncologyMember
pfe:ElrexfioMember
pfe:BiopharmaSegmentMember
2023-01-01
2023-12-31
0000078003
pfe:OncologyMember
pfe:ElrexfioMember
pfe:BiopharmaSegmentMember
2022-01-01
2022-12-31
0000078003
pfe:OncologyMember
pfe:TivdakMember
pfe:BiopharmaSegmentMember
2024-01-01
2024-12-31
0000078003
pfe:OncologyMember
pfe:TivdakMember
pfe:BiopharmaSegmentMember
2023-01-01
2023-12-31
0000078003
pfe:OncologyMember
pfe:TivdakMember
pfe:BiopharmaSegmentMember
2022-01-01
2022-12-31
0000078003
pfe:OncologyMember
pfe:TalzennaMember
pfe:BiopharmaSegmentMember
2024-01-01
2024-12-31
0000078003
pfe:OncologyMember
pfe:TalzennaMember
pfe:BiopharmaSegmentMember
2023-01-01
2023-12-31
0000078003
pfe:OncologyMember
pfe:TalzennaMember
pfe:BiopharmaSegmentMember
2022-01-01
2022-12-31
0000078003
pfe:OncologyMember
pfe:OtherOncologyProductsMember
pfe:BiopharmaSegmentMember
2024-01-01
2024-12-31
0000078003
pfe:OncologyMember
pfe:OtherOncologyProductsMember
pfe:BiopharmaSegmentMember
2023-01-01
2023-12-31
0000078003
pfe:OncologyMember
pfe:OtherOncologyProductsMember
pfe:BiopharmaSegmentMember
2022-01-01
2022-12-31
0000078003
pfe:PfizerCentreOneMember
2024-01-01
2024-12-31
0000078003
pfe:PfizerCentreOneMember
2023-01-01
2023-12-31
0000078003
pfe:PfizerCentreOneMember
2022-01-01
2022-12-31
0000078003
pfe:PfizerIgniteMember
2024-01-01
2024-12-31
0000078003
pfe:PfizerIgniteMember
2023-01-01
2023-12-31
0000078003
pfe:PfizerIgniteMember
2022-01-01
2022-12-31
0000078003
pfe:BiopharmaSegmentMember
pfe:U.S.CommercialDivisionMember
2024-01-01
2024-12-31
0000078003
pfe:BiopharmaSegmentMember
pfe:U.S.CommercialDivisionMember
2023-01-01
2023-12-31
0000078003
pfe:BiopharmaSegmentMember
pfe:U.S.CommercialDivisionMember
2022-01-01
2022-12-31
0000078003
pfe:BiopharmaSegmentMember
pfe:OncologyDivisionMember
2024-01-01
2024-12-31
0000078003
pfe:BiopharmaSegmentMember
pfe:OncologyDivisionMember
2023-01-01
2023-12-31
0000078003
pfe:BiopharmaSegmentMember
pfe:OncologyDivisionMember
2022-01-01
2022-12-31
0000078003
pfe:BiopharmaSegmentMember
pfe:InternationalCommercialDivisionMember
2024-01-01
2024-12-31
0000078003
pfe:BiopharmaSegmentMember
pfe:InternationalCommercialDivisionMember
2023-01-01
2023-12-31
0000078003
pfe:BiopharmaSegmentMember
pfe:InternationalCommercialDivisionMember
2022-01-01
2022-12-31
0000078003
pfe:TotalAllianceBiopharmaceuticalsMember
2024-01-01
2024-12-31
0000078003
pfe:TotalAllianceBiopharmaceuticalsMember
2023-01-01
2023-12-31
0000078003
pfe:TotalAllianceBiopharmaceuticalsMember
2022-01-01
2022-12-31
0000078003
pfe:PaxlovidEUALabeledMember
2024-01-01
2024-12-31
0000078003
pfe:SpecialtyCareMember
pfe:CommercializationPartnerMember
pfe:OctagamMember
pfe:BiopharmaSegmentMember
2024-01-01
2024-12-31
0000078003
pfe:ComirnatyMember
2024-12-31
0000078003
pfe:PaxlovidMember
2024-12-31
0000078003
pfe:GovernmentAndGovernmentSponsoredMember